Dr. Frederick Sancilio reports

LOBE SCIENCES LTD. ANNOUNCES UPSIZE TO NON-BROKERED PRIVATE PLACEMENT

Lobe Sciences Ltd. has upsized its previously announced non-brokered private placement offering of common shares in the capital of the company at a price of 8.5 cents per common share.

The company closed the first tranche of the private placement on Aug. 19, 2026, through the issuance of 24,705,880 for gross proceeds of $2.1-million. As a result of further demand, the company intends to close an additional tranche of the private placement, composed of 705,882 shares for gross proceeds of approximately $60,000. Assuming closing of the second tranche, the company will have issued an aggregate of 25,411,762 shares for gross proceeds of $2.16-million pursuant to the private placement.

The company intends to use the proceeds of the private placement for working capital and general corporate purposes and to advance its S-100 drug candidate for the treatment of sickle cell disease. A portion of the proceeds will be directed to its subsidiary, Applied Lipid Technologies Inc., to support development of the S-100 program toward human clinical trials. The company has procured the active pharmaceutical ingredient required for these studies, enabling the program to move forward.

The second tranche remains subject to receipt of all necessary regulatory approvals, including acceptance by the Canadian Securities Exchange. All securities issued in connection with the second tranche will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

About Lobe Sciences Ltd.

Lobe Sciences is a biopharmaceutical company advancing programs in diseases with unmet medical needs. The company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (formerly Altemia Inc.).

We seek Safe Harbor.